Maze Therapeutics, Inc. (MAZE) AI Stock Analysis

• Market Cap: $585.41M
• Dividend Yield: N/A
• Average Volume (3M): 147.29K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.82
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 125
• Sector: Healthcare
• Sector Strength: 43
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 43,850,883
• 10 Day Avg. Volume: 186,068
• 30 Day Avg. Volume: 147,288
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.51
• Enterprise Value/Revenue: 119.41
• Enterprise Value/Gross Profit: 646.14
• Enterprise Value/Ebitda: -2.40
• 1Y Price Target: $26.75
• Price Target Upside: 100.37% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5

• Rating: 59 Neutral
• Price Target: ―

Maze Therapeutics shows strong financial performance with significant revenue and cash flow improvements, yet the negative equity presents a substantial risk. Technical indicators suggest potential weakness in stock momentum, and lack of valuation metrics prevents a comprehensive assessment. Overall, the stock's strengths in financial growth are tempered by balance sheet risks and technical analysis concerns.

Positive Factors

Clinical Trials

Management plans to launch two parallel Phase II studies in PKU and CKD based on the Phase I results.

Drug Potency

MZE782 is 3-4x more potent against human SLC6A19 than JNT-517 in an in vitro leucine uptake assay.

Financial Outlook

Positive sentiment remains on Maze, with upcoming catalysts and ample cash to provide runway for 2+ years.

Negative Factors

Investor Engagement

Interest in the company is expected to pick up in the near term due to anticipated catalysts from both lead programs over the next few quarters.

Market Valuation

The stock is considered undervalued at the current valuation, given the strong human genetics evidence supporting the SLC6A19 approach.

Maze Therapeutics, Inc. Business Overview & Revenue Model

Company Description

Maze Therapeutics, Inc. (MAZE) is a biotechnology company focused on translating genetic insights into novel therapeutic approaches for treating a range of diseases. Operating within the biotechnology and pharmaceutical sectors, Maze leverages its proprietary COMPASS platform to identify and validate genetic modifiers, which are then developed into potential therapeutic products. The company's core focus is on discovering genetic pathways that can be modulated to treat diseases with significant unmet medical needs.

How the Company Makes Money

Maze Therapeutics generates revenue through a combination of strategic partnerships, collaborations, and the development and commercialization of its own therapeutic products. The company partners with other biotech and pharmaceutical companies to co-develop therapies, often receiving milestone payments and royalties from these collaborations. Additionally, Maze invests in its proprietary drug development programs, aiming to bring its therapies to market and generate revenue from product sales. The company's revenue model is heavily reliant on research and development success, regulatory approvals, and the establishment of lucrative partnerships that provide funding and market access for its innovations.

Maze Therapeutics, Inc. Financial Statement Overview

Summary

Maze Therapeutics exhibits robust revenue and cash flow growth, marking a significant turnaround from prior years. However, the balance sheet remains weak with negative equity, indicating potential financial risk. Despite profitability and operational efficiency, high leverage and negative equity could pose challenges to long-term stability.

Income Statement

Maze Therapeutics experienced significant improvement with revenue reaching $167.5M in 2024, up from zero in previous years, representing a strong revenue growth. Gross Profit Margin is 100% due to revenue equaling gross profit, indicating excellent cost management. Net Profit Margin is 31.2%, reflecting profitability. EBIT and EBITDA margins are healthy at 34.4% and 36.3%, respectively, demonstrating efficient operations.

Balance Sheet

The company has a negative stockholders' equity of -$311.18M, indicating financial instability. Debt-to-Equity ratio is not calculable due to negative equity. The equity ratio is negative, reflecting high leverage and potential financial risk. However, the company has substantial cash reserves, with cash holdings exceeding total debt.

Cash Flow

Maze Therapeutics shows strong cash flow performance with a substantial improvement in operating cash flow to $75.95M in 2024, up from a negative position. Free Cash Flow is positive at $74.81M, indicating effective cash management. Operating Cash Flow to Net Income ratio is 1.45, suggesting efficient conversion of income to cash.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022
Income Statement
Total Revenue	2.50M	167.50M	0.00	0.00
Gross Profit	462.00K	167.50M	-4.09M	-3.82M
EBITDA	-124.34M	60.88M	-94.46M	-107.21M
Net Income	-120.80M	52.23M	-100.42M	-114.94M
Balance Sheet
Total Assets	303.52M	240.54M	71.50M	149.96M
Cash, Cash Equivalents and Short-Term Investments	264.54M	196.81M	29.16M	99.92M
Total Debt	25.01M	26.63M	49.62M	32.05M
Total Liabilities	41.28M	551.73M	445.35M	432.42M
Stockholders Equity	262.24M	-311.18M	-373.85M	-282.46M
Cash Flow
Free Cash Flow	-106.63M	74.81M	-87.27M	-101.17M
Operating Cash Flow	-105.22M	75.95M	-86.83M	-99.20M
Investing Cash Flow	-1.40M	-1.15M	-441.00K	-3.17M
Financing Cash Flow	196.10M	92.85M	16.39M	1.73M

Maze Therapeutics, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MAZE	59 Neutral	$585.41M	―		―	―	―
Sector *	57 Neutral	£5.18B	4.93	-44.55%	2.33%	28.89%	-10.08%
SAGE	54 Neutral	$543.61M	―	-60.43%	―	-27.59%	34.00%
AKBA	49 Neutral	$872.33M	―	91.25%	―	16.75%	14.72%
SVRA	46 Neutral	$520.24M	―	-99.30%	―	―	-21.05%
OMER	40 Underperform	$276.56M	―	87.26%	―	―	-33.92%